294 related articles for article (PubMed ID: 12188426)
21. [Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies].
Perret BA; Poorbeik M; Morell A
Schweiz Med Wochenschr; 1991 Nov; 121(44):1624-7. PubMed ID: 1947960
[TBL] [Abstract][Full Text] [Related]
22. Exchange transfusion and pulse steroid therapy in a hemophiliac with inhibitor.
Chuansumrit A; Isarangkura P; Krutvecho T; Hathirat P; Pintadit P
J Med Assoc Thai; 1989 Jan; 72 Suppl 1():139-43. PubMed ID: 2499649
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
[TBL] [Abstract][Full Text] [Related]
24. Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate.
Smit Sibinga CT; Daenen SM; van Imhoff GW; Maas A; Das PC
Thromb Haemost; 1984 Feb; 51(1):12-5. PubMed ID: 6426077
[TBL] [Abstract][Full Text] [Related]
25. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.
Vlot AJ; Mauser-Bunschoten EP; Zarkova AG; Haan E; Kruitwagen CL; Sixma JJ; van den Berg HM
Thromb Haemost; 2000 Jan; 83(1):65-9. PubMed ID: 10669157
[TBL] [Abstract][Full Text] [Related]
26. Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
Benny AG; Ockelford PA; Johns AS; Scott RH; Woodfield DG; Berry EW
J Clin Pathol; 1988 Sep; 41(9):945-7. PubMed ID: 3142936
[TBL] [Abstract][Full Text] [Related]
27. In vivo characteristics of thaw siphon cryoprecipitate compared to other factor VIII preparations.
Toolis F; McKay G; Prowse CV
Thromb Haemost; 1980 Feb; 43(1):25-7. PubMed ID: 6773169
[TBL] [Abstract][Full Text] [Related]
28. Response of hemophilia A with bleeding to fresh dry plasma.
Krutvacho T; Chuansumrit A; Isarangkura P; Pintadit P; Hathirat P; Chiewsilp P
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():169-73. PubMed ID: 7886565
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran.
Daliri AA; Haghparast H; Mamikhani J
Int J Technol Assess Health Care; 2009 Oct; 25(4):584-7. PubMed ID: 19845990
[TBL] [Abstract][Full Text] [Related]
30. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
[TBL] [Abstract][Full Text] [Related]
31. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.
Over J; Sixma JJ; Bruïne MH; Trieschnigg MC; Vlooswijk RA; Beeser-Visser NH; Bouma BN
J Clin Invest; 1978 Aug; 62(2):223-34. PubMed ID: 670391
[TBL] [Abstract][Full Text] [Related]
32. Home therapy for hemophilia in Thailand.
Isarangkura P; Chuansumrit A; Panthangkura W; Hathirat P; Pandhawong S
Southeast Asian J Trop Med Public Health; 1987 Dec; 18(4):552-7. PubMed ID: 3448780
[TBL] [Abstract][Full Text] [Related]
33. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections.
Bidlingmaier C; Deml MM; Kurnik K
Haemophilia; 2006 May; 12(3):212-7. PubMed ID: 16643203
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study.
Nemes L; Lissitchkov T; Dobaczewski G; Klukowska A; Komrska V; Zimmermann R; Auerswald G; Engl W; Abbühl B; Pavlova BG; Ehrlich HJ
Acta Haematol; 2008; 119(2):89-97. PubMed ID: 18305381
[TBL] [Abstract][Full Text] [Related]
35. National survey of patients with hemophilia and other congenital bleeding disorders in Thailand.
Chuansumrit A; Mahasandana C; Chinthammitr Y; Pongtanakul B; Laossombat V; Nawarawong W; Lektakul Y; Wangruangsatid S; Sriboriboonsin L; Rojnakarin P; Angchaisuksiri P;
Southeast Asian J Trop Med Public Health; 2004 Jun; 35(2):445-9. PubMed ID: 15691153
[TBL] [Abstract][Full Text] [Related]
36. Use of 'single donor' factor VIII from plasma exchange donation.
McLeod BC; Scott JP
JAMA; 1984 Nov; 252(19):2726-9. PubMed ID: 6436520
[TBL] [Abstract][Full Text] [Related]
37. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
38. Preparation of pooled cryoprecipitate for treatment of hemophilia A in a home care program.
Smith KJ; Hodges PA
Transfusion; 1984; 24(6):520-3. PubMed ID: 6438840
[TBL] [Abstract][Full Text] [Related]
39. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
40. Factor VIII half-life and intensity of treatment in hemophilic patients.
Vicente V
Haematologica; 2005 Apr; 90(4):437. PubMed ID: 15820932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
